Alphamab Oncology 2020 SR
The report highlights Alphamab Oncology's progress in 2020, including the submission of the Biologic License Application for KN035 and the initiation of Phase III clinical trials for KN046. The company expanded its production capabilities with a new Drug Production License for its Phase I production line and established strategic collaborations with Pfizer, Sanofi, and others. Environmental efforts focused on energy saving and water recycling, while social initiatives included a RMB 1,000,000 donation to support COVID-19 relief. The company also emphasized its R&D strength, with R&D personnel accounting for 75% of the total workforce.
Company: Alphamab Oncology
Sector: Manufacturing
Country: China
Year: 2020
Type: SR
Pages: 43
Back to company
Alphamab Oncology
ESG Report
The report highlights Alphamab Oncology's progress in 2020, including the submission of the Biologic License Application for KN035 and the initiation of Phase III clinical trials for KN046. The company expanded its production capabilities with a new Drug Production License for its Phase I production line and established strategic collaborations with Pfizer, Sanofi, and others. Environmental efforts focused on energy saving and water recycling, while social initiatives included a RMB 1,000,000 donation to support COVID-19 relief. The company also emphasized its R&D strength, with R&D personnel accounting for 75% of the total workforce.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees